EDAP TMS S.A. (EDAP) has released an update.
EDAP TMS S.A. has reported significant revenue growth for Q4 and the full year of 2023, with a standout 24.8% increase in Q4 and a strong performance in the HIFU business, buoyed by robust procedure growth in the U.S. The company, a leader in robotic energy-based therapies, anticipates further adoption of its Focal One technology and has received FDA Breakthrough Device designation for treating deep infiltrating endometriosis, signaling a promising outlook for 2024.
For further insights into EDAP stock, check out TipRanks’ Stock Analysis page.
